The economic cost of Alzheimer’s disease. Family or public-health burden?

Fuente: Redalyc
Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Diego M. Castro
Format: Artículo científico
Sprache:en
Veröffentlicht: Associação Neurologia Cognitiva e do Comportamento 2010
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1876485669928304640
author Diego M. Castro
author_facet Diego M. Castro
contents The economic cost of Alzheimer’s disease. Family or public-health burden? Diego M. Castro Carol Dillon Gerardo Machnicki Ricardo F. Allegri Medicina economic costs health economics Alzheimer’s disease Alzheimer’s disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options. 2010 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339529019003 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.4 Vol.4
format Artículo científico
id redalyc_339529019003
institution Redalyc
language en
publishDate 2010
publisher Associação Neurologia Cognitiva e do Comportamento
spellingShingle The economic cost of Alzheimer’s disease. Family or public-health burden?
Diego M. Castro
Medicina
economic costs
health economics
Alzheimer’s disease
The economic cost of Alzheimer’s disease. Family or public-health burden? Diego M. Castro Carol Dillon Gerardo Machnicki Ricardo F. Allegri Medicina economic costs health economics Alzheimer’s disease Alzheimer’s disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options. 2010 artículo científico 1980-5764 https://www.redalyc.org/articulo.oa?id=339529019003 en http://www.redalyc.org/revista.oa?id=3395 Dementia & Neuropsychologia application/pdf Associação Neurologia Cognitiva e do Comportamento Dementia & Neuropsychologia (Brasil) Num.4 Vol.4
title The economic cost of Alzheimer’s disease. Family or public-health burden?
topic Medicina
economic costs
health economics
Alzheimer’s disease
url https://www.redalyc.org/articulo.oa?id=339529019003